CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Further studies are therefore required to identify the antigenic culprits that trigger T-LGLL and characterize the dominant CD8+ TCR-Vβ+ expansions that potentially cause autoimmune side-effects and/or beneficially target leukemic cells in dasatinib-treated CML patients46.